STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

FOSTEMSAVIR

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FOSTEMSAVIR	RUKOBIA	46684		GPI-10 (1210233040)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of human immunodeficiency virus type 1 (HIV-1) infection and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The requested medication will be used in combination with other antiretroviral(s)
   - The patient is heavily treatment experienced and has multidrug-resistant HIV-1 infection
   - The patient is failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.
   Our guideline named **FOSTEMSAVIR (Rukobia)** requires the following rule(s) be met for approval:
   A. You have human immunodeficiency virus type 1 (HIV-1) infection
   B. You are 18 years of age or older
   C. The requested medication will be used in combination with other antiretroviral(s) (class of medication used to treat HIV)
   D. You are heavily treatment experienced (previously treated) and have multidrug-resistant HIV-1 infection
   E. You are failing your current antiretroviral regimen due to resistance, intolerance, or safety considerations

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rukobia.

REFERENCES

Rukobia [Prescribing Information]. Research Triangle Park, NC: GlaxoSmithKline; July 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A
Commercial Effective:07/17/20
Created: 07/20
Client Approval: 07/20
P&T Approval:07/20